The humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory MM.

"As a leader in hematologic malignancies, AbbVie is committed to advancing innovative treatments for complex cancers like multiple myeloma through our relentless (research and development ...

AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for multiple myeloma. The companies have entered into an option to licence ...

AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and ...

SIM0500 has shown strong T cell cytotoxicity against multiple myeloma (MM) cells by leveraging a combination of various antitumor effects. "As a leader in hematologic malignancies, AbbVie is ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion ...

and SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV ... clinical trials in patients with relapsed or refractory multiple myeloma (MM), in both China and the U.S. SIM0500 is a humanized ...

SIM0500 has shown strong T cell cytotoxicity against multiple myeloma (MM) cells by leveraging a combination of various antitumor effects. "As a leader in hematologic malignancies, AbbVie is ...